What's Happening?
Federico Pio Fabrizio, Associate Professor of Molecular Biology at the Department of Medicine and Surgery at Kore University of Enna, along with colleagues, has published a Viewpoint in JAMA Oncology titled 'Why Harmonizing NGS Panels Is the Missing Link
in Precision Oncology – One Genome, Too Many Standards.' The article highlights significant disparities in genomic testing practices, including variations in laboratory infrastructure, expertise, financial resources, and reimbursement policies. These discrepancies influence the selection of Next-Generation Sequencing (NGS) panels and testing methods both within and across countries. Smaller centers, in particular, may be limited to hotspot panels, potentially overlooking crucial actionable alterations and denying patients access to targeted therapies or biomarker-driven clinical trials. The researchers emphasize that fully realizing the clinical potential of precision oncology requires standardized, reliable, and equitable access to genomic testing, with harmonized NGS workflows being critical for improving reliability and comparability of results.
Why It's Important?
The lack of standardized NGS panels in precision oncology has profound implications for patient care and the advancement of cancer treatment in the U.S. and globally. Inconsistent testing practices can lead to unequal access to cutting-edge therapies, as patients in smaller or less-resourced centers may not receive comprehensive genomic profiling. This can result in missed opportunities for personalized treatments that could significantly improve outcomes. Furthermore, the absence of harmonized workflows hinders the comparability of research data across different institutions, slowing down the pace of discovery and the development of new therapies. Equitable reimbursement policies are also crucial, as financial barriers currently prevent many patients from accessing necessary genomic testing. Addressing these issues is vital for ensuring that all cancer patients, regardless of their location or socioeconomic status, can benefit from the latest advancements in precision oncology.
What's Next?
The Viewpoint by Professor Fabrizio and his team outlines several key priorities for the future of precision oncology. These include establishing shared minimum testing standards, implementing standardized reporting mechanisms, clearly defining clinically validated classes of genomic alterations, developing equitable reimbursement policies, and ensuring continuous updates aligned with clinical practice guidelines. The ongoing development of AI-assisted platforms, such as Turnkey Precision Oncology, which analyze DNA and RNA sequencing data to generate evidence-supported molecular pathology reports, is expected to play a significant role in standardizing and improving genomic testing. Additionally, implementation science theories and frameworks are being explored to support the translation of evidence-based genomics applications into clinical practice, particularly in pediatric precision oncology, reproductive genetic carrier screening, and population genomic screening for hereditary conditions. These efforts aim to overcome existing discrepancies and promote a more unified approach to genomic testing.
Beyond the Headlines
The call for harmonized NGS panels extends beyond mere technical standardization; it touches upon ethical and societal considerations regarding equitable healthcare access. The current disparities highlight a systemic challenge where advanced medical technologies are not uniformly available, creating a divide in patient care. This situation underscores the need for a collaborative effort involving policymakers, healthcare providers, researchers, and industry stakeholders to develop and enforce universal standards. The integration of AI and implementation science suggests a future where technology and structured methodologies can bridge these gaps, ensuring that the promise of precision oncology—tailored treatments based on an individual's genetic makeup—is realized for all. This shift could lead to a more just healthcare system where access to life-saving genomic information is not dictated by geographical or financial constraints.
